{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"Calidi Biotherapeutics Announces Proposed Public Offering - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"5ntKlbGZOM\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-announces-proposed-public-offering\/\">Calidi Biotherapeutics Announces Proposed Public Offering<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-announces-proposed-public-offering\/embed\/#?secret=5ntKlbGZOM\" width=\"600\" height=\"338\" title=\"&#8220;Calidi Biotherapeutics Announces Proposed Public Offering&#8221; &#8212; Market Newsdesk\" data-secret=\"5ntKlbGZOM\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) &#8212; Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (\u201cCalidi\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies,\u00a0today announced that it intends to offer to sell shares of its common stock (and\/or pre-funded warrants (\u201cPre-Funded Warrants\u201d) in lieu thereof) in an public offering. All of the shares of common stock (and\/or Pre-funded Warrants) are to be sold by the Company. Ladenburg\u00a0Thalmann\u00a0&amp; Co. Inc. is acting as exclusive placement agent for the offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Calidi intends to &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODkzOCM2Njg1NDY0IzIxOTM4NTQ="}